Tarlatamab was given accelerated approval in May 2024 for extensive-stage small cell lung cancer (SCLC). How does this therapy work, and what was the important data the led to its approval?
- What are the main adverse events to watch for, and do you manage them?
- Are there any other clinical considerations, such as inpatient or outpatient dosing, when using a bispecific T-cell engager like tarlatamab?
- Where does this therapy fit into your treatment algorithm for patients with SCLC?